Mycronic AB

Mycronic AB is a Swedish manufacturer of electronics assembly equipment headquartered in Täby, near Stockholm, and listed on Nasdaq Stockholm (MYCR). Founded in 1989, the company generated SEK 7.938 billion (approximately USD 750 million) in 2025 net sales, up 12% year-on-year, with operating profit (EBIT) of SEK 1.940 billion and a 24% margin. Employing 2,673 people and operating through direct sales and agents in nearly 50 countries, Mycronic holds dominant positions in solder paste jet printing and high-mix/low-volume placement.

Business Overview

Mycronic's electronics assembly business splits into two roughly equal halves. PCB Assembly Solutions (22% of group sales) centers on the MYPro series flexible placement machines and the pioneering jet printing technology, which deposits solder paste without stencils — an approach ideally suited to complex, low-volume, high-reliability boards used in aerospace, medical, defense, and communications equipment. High Volume (22% of sales) is anchored by the Chinese subsidiary Axxon, which manufactures high-speed dispensing equipment for consumer electronics and automotive production. The remainder of the group includes mask writers for display and semiconductor manufacturing.

2025 was a year of strong performance and strategic expansion. Net sales grew 12% to SEK 7.938 billion, driven by AI-related applications and global technology investment, while the operating margin held at a sector-leading 24%. In Q1 2026 the company recorded its highest quarterly operating profit ever, prompting the board to raise full-year 2026 guidance to SEK 8.75 billion. Operationally, Mycronic completed the relocation and expansion of its Kista production line, commissioned a new factory in Thailand, and completed the acquisition of German test-probe manufacturer ETZ to broaden its PCB test portfolio.

Core Strengths

Mycronic's deepest competitive advantage is its jet printing technology. Because jet printing requires no stencils, it eliminates setup cost and lead time for complex boards, making it effectively the only viable solution for many aerospace, medical, and military applications — giving Mycronic pricing power and customer stickiness that placement-machine vendors cannot replicate. In the high-mix/low-volume placement segment, the MYPro series' rapid changeover capability similarly commands a premium, as factories increasingly shift toward flexible production.

Innovation keeps the moat fresh. The GenI system, unveiled in 2025-2026, applies generative AI to AOI programming, potentially slashing the engineering effort required to set up inspection processes — a breakthrough that could accelerate adoption across the entire inspection market. The ETZ acquisition adds PCB testing capability, moving Mycronic further along the line toward full-process solutions. Operationally, the Thailand factory and Swedish expansion diversify geographic production risk, while the 24% EBIT margin provides ample self-funding capacity.

Risks & Outlook

The principal near-term risk is China. Management indefinitely shelved the planned IPO of the Axxon subsidiary on the Chinese stock exchange, citing the depressed local capital market, which limits funding flexibility and signals softness in the Chinese electronics sector. The High Volume segment's growth is consequently more dependent on global consumer electronics cycles than on Chinese expansion. As a specialist, Mycronic also carries concentration risk: its fortunes track the high-mix electronics niche, which is more sensitive to macroeconomic cycles than mass-production lines.

The outlook, however, is strongly positive. Record Q1 2026 results and upgraded guidance reflect accelerating AI-driven demand across its customer base, while the GenI AI inspection system and ETZ test portfolio open new growth vectors. The company's 24% operating margin, strong balance sheet, and leadership in two defensible niches position it well to compound growth for years. VerityRank Score of 85/100